Psychedelics
December 23, 2025
Esenia K. Cassidy, Alan K. Davis, Smitha Rao
Attachment theory holds that early caregiver interactions shape lifelong mental health, substance use, and well-being. This critical literature review synthesizes 21 peer-reviewed studies on attachment and psychedelics published by November 30, 2024. Identified themes include attachment as a predictor and outcome of psychedelic effects, relationality and romantic relationships, traumatic attachment and grief, clinical implications, calls to expand research into religion and spirituality, and passionate attachment to substances. Common limitations are demographic homogeneity, reliance on self-report, inconsistent study conditions, uncritical positivist approaches, and lack of discussion of limitations or positionalities. More diverse and rigorous research is needed, with greater epistemological awareness and reflexivity.
Psychedelics
November 15, 2025
Meghan DellaCrosse, Shoval Gilead, Rafael Lancelotta et al.
Spanish-speaking individuals who had a memorable psilocybin or LSD experience reported two main themes: deep connection (to nature, others, the present moment, and the substance) and emotion-related experiences (from joy and peace to emotional processing, catharsis, and challenging experiences). The findings are based on a secondary qualitative analysis of open-ended survey responses from 379 Spanish-speaking participants. Similarities appeared across both substances, with some unique nuances. The work underscores the need for diverse populations in psychedelic research to improve generalizability and cultural relevance, and highlights the therapeutic potential of psychedelics while calling for culturally sensitive tools.
November 4, 2024
Jacob S. Aday, Jenna McAfee, Deirdre A. Conroy et al.
preprint
In a small open-label proof-of-concept trial, five adults with fibromyalgia received two doses of psilocybin (15 mg and 25 mg) two weeks apart, along with psychotherapy sessions. No serious adverse events occurred; transient blood pressure or heart rate elevations during dosing resolved by the end of treatment, and four of five participants had temporary headaches. One month after the second dose, participants reported clinically meaningful improvements in pain severity, pain interference, and sleep disturbance. One participant rated their symptoms as very much improved, two as much improved, and two as minimally improved. Improvements were also seen in fibromyalgia symptoms, anxiety, and fatigue. The findings suggest psilocybin-assisted therapy is well-tolerated and warrants larger randomized controlled trials.
Journal of Psychedelic Studies
September 17, 2024
Adam W. Levin, Aryan Sarparast, Paul B Nagib et al.
Among a sample of 180 American psychiatrists (mean age 48.4, 65.5% male, 24.1% trainees), about one-third (32.8%) reported personal use of and social connection to psychedelics. Psychiatrists with such personal connection tended to be younger and have fewer years of practice. Those with personal and social connection were more likely to disagree that using illegal drugs is morally wrong, that users should go to prison, are weak-minded, have no future, are poorly educated, are dishonest, or make them angry. Personal and social proximity to psychedelics is associated with less stigma toward drug use and people who use drugs.
Drug and Alcohol Dependence
July 1, 2024
Alan K. Davis, Adam W. Levin, Rafael Lancelotta et al.
No Summary
August 22, 2022
John M. Pederson, Kathryn Cowie, Averi Barrett et al.
A living systematic review and individual patient data meta-analysis is planned to assess the efficacy and safety of psilocybin for major depressive disorder (MDD). The review will include randomized and non-randomized trials, searching major databases and trial registries, and will analyze primary outcomes of depression severity using validated scales, with secondary outcomes including anxiety, hopelessness, quality of life, and death acceptance. Hierarchical mixed-effects models will account for clustering across studies and examine moderators like age, sex, baseline severity, prior psilocybin use, and dose. The review will be updated continuously as new evidence emerges to inform clinical practice and policy.
Journal of Psychedelic Studies
May 28, 2026
Rafaelle L. Lancelotta, Paul B. Nagib, Stacey B. Armstrong et al.
A methodology for designing and evaluating a music playlist for a clinical psilocybin trial was developed, combining theory, therapeutic goals, and metrics. The playlist was structured across pre-peak, peak, and post-peak phases of the psilocybin experience. Spotify API metrics (Beats Per Minute, Danceability, Energy, Valence) and a novel human-rated Transcendence measure were used to assess tracks. Most musical features followed the expected emotional arc of the psilocybin experience, but nature-based tracks were sometimes misclassified as high-energy by the Spotify API, revealing algorithmic limitations. Transcendence ratings indicated continued emotional depth during post-peak phases. This proof-of-concept model shows the value of integrating intentional design with algorithmic and experiential metrics, though Spotify metrics may lack stability and generalizability.